The DOI matches its Crossref record.
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial
Open accessAbstract
BACKGROUND: Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein in development for the prophylaxis of hereditary angioedema (HAE) attacks. OBJECTIVE: Our aim was to determine the efficacy, safety, and tolerability of berotralstat in patients with HAE over a 24-week treatment period (the phase 3 APeX-2 trial). METHODS: APeX-2 was a double-blind, parallel-group study that randomized patients at 40 sites in 11 countries 1:1:1 to receive once-daily berotralstat in a dose of 110 mg or 150 mg or placebo (Clinicaltrials.gov identifier NCT03485911). Patients aged 12 years or older with HAE due to C1 inhibitor deficiency and at least 2 investigator-confirmed HAE attacks in the first 56 days of a prospective run-in period were eligible. The primary efficacy end point was the rate of investigator-confirmed HAE attacks during the 24-week treatment period. RESULTS: A total of 121 patients were randomized; 120 of them received at least 1 dose of the study drug (n = 41, 40, and 39 in the 110-mg dose of berotralstat, 150-mg of dose berotralstat, and placebo groups, respectively). Berotralstat demonstrated a significant reduction in attack rate at both 110 mg (1.65 attacks per month; P = .024) and 150 mg (1.31 attacks per month; P < .001) relative to placebo (2.35 attacks per month). The most frequent treatment-emergent adverse events that occurred more with berotralstat than with placebo were abdominal pain, vomiting, diarrhea, and back pain. No drug-related serious treatment-emergent adverse events occurred. CONCLUSION: Both the 110-mg and 150-mg doses of berotralstat reduced HAE attack rates compared with placebo and were safe and generally well tolerated. The most favorable benefit-to-risk profile was observed at a dose of 150 mg per day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Maurer, M., Magerl, M., Betschel, S., Aberer, W., Ansotegui, I. J., Aygören‐Pürsün, E., Banerji, A., Bara, N., Boccon‐Gibod, I., Bork, K., et al. (2022) · Allergy · doi:10.1111/all.15214 · Cited by 534
Self-citationThe Expanding Spectrum of Mutations in Hereditary Angioedema
Veronez, C. L., Csuka, D., Sheikh, F. R., Zuraw, B. L., Farkas, H., & Bork, K. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.03.008 · Cited by 57
Self-citation
Metadata
- Authors
- Zuraw, B., Lumry, W. R., Johnston, D. T., Aygören-Pürsün, E., Banerji, A., Bernstein, J. A., Christiansen, S. C., Jacobs, J. S., Sitz, K. V., Gower, R. G., Gagnon, R., Wedner, H. J., Kinaciyan, T., Hakl, R., Hanzlíková, J., Anderson, J. T., McNeil, D. L., Fritz, S. B., Yang, W. H., Tachdjian, R., Busse, P. J., Craig, T. J., Li, H. H., Farkas, H., Best, J. M., Clemons, D., Cornpropst, M., Dobo, S. M., Iocca, H. A., Kargl, D., Nagy, E., Murray, S. C., Collis, P., Sheridan, W. P., Maurer, M., & Riedl, M. A.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 148
- Issue
- 1
- Pages
- 164-172.e9
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W3093864427
- Cited by
- 176
- References
- 0
- FWCI
- 9.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. https://app.cochat.ai/papers/10.1016/j.jaci.2020.10.015
- The paper
- Zuraw, B., Lumry, W. R., Johnston, D. T., Aygören-Pürsün, E., Banerji, A., Bernstein, J. A., Christiansen, S. C., Jacobs, J. S., Sitz, K. V., Gower, R. G., Gagnon, R., Wedner, H. J., Kinaciyan, T., Hakl, R., Hanzlíková, J., Anderson, J. T., McNeil, D. L., Fritz, S. B., Yang, W. H., . . . Riedl, M. A. (2021). Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2020.10.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.